Title
Category
Credits
Event date
Cost
  • AMA PRA Category 1 Credit™
  • Participation
10/04/2021
$0.00
Did you miss this activity? Tune in for the rebroadcast on October 28! Click here
  • Oncology
  • ANCC
  • Participation
10/06/2021
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
10/08/2021
$0.00
Attendees of these regional meetings will gain an appreciation of the genes involved in the DNA damage response pathways and their role in tumorigenesis, the latest guidelines on genetic testing/counseling for mutations in this pathway, and the clinical implications of testing results (such as the use of PARP inhibitor for treatment). There will also be extensive discussion about the evolving role of the OB/GYN practitioner in genetic testing/counseling and management of ovarian cancer survivors on PARP inhibitor therapy.Presented by Creative Educational Concepts, Inc.
  • Oncology
  • ACPE Pharmacy
  • Participation
10/14/2021
$0.00
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • Oncology
  • ANCC
  • Participation
10/16/2021
$0.00
Nurse and physician expert faculty will discuss the emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • Participation
10/18/2021
$0.00
This timely, adaptive, and dynamic educational activity is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 Academy of Managed Care Pharmacy (AMCP) Nexus meeting. Activity attendees will be given the opportunity to interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency anemia (IDA) management in chronic kidney disease (CKD).
  • Oncology
  • ACPE Pharmacy
  • Participation
10/20/2021
$0.00
Attendees of this initiative will gain exposure to emerging advances in the treatment of chronic lymphocytic leukemia (CLL) with novel agents targeting the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for monotherapy and combination therapy strategies for CLL in first- and later-line settings. Attendees will understand how to differentiate between the different novel agents available with regard to efficacy, adverse event profile, and other relevant clinical factors.
  • AMA PRA Category 1 Credit™
  • Participation
10/28/2021
$0.00
This educational activity is targeted to pediatric neurologists, neuro-oncologists, neurosurgeons, and other members of the multidisciplinary NF1 care team attending the 2021 Child Neurology Society (CNS) Annual Meeting.
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
12/10/2021
$0.00
This timely, adaptive, and dynamic educational activity is targeted to hematologists, oncologists, heme/onc residents/fellows, and the interprofessional hematology/oncology care team of nurse practitioners, physician assistants, pharmacists, and nurses. Activity attendees will be given the opportunity to interact with world-renowned expert faculty across all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA).

Pages